AXIM® Biotech Discusses Patented Cannabinoid-Release Chewing Gum – MedChew RX™; Future Patent-Pending Products Including: Oral Care, Skin Care, Suppository, and Ocular Treatments
SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM® Biotechnologies, Inc. (OTC:AXIM), participated in a recent interview and unveiled the hemp innovator’s intellectual property (IP)-protected cannabis-based research and product development roadmap.
“We are extremely enthusiastic about AXIM Biotech’s position in the cannabis industry as a leader in cannabinoid research and development,” states Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc. “Their efforts have the potential to expedite cannabis’ return to the global healthcare market, as early as 2017.” Listen to the interview below:
AXIM® Biotech’s Chief Executive Officer, Dr. George E. Anastassov, MD, DDS, MBA, explains in the interview the unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.).
The Company’s goal is finding solutions for conditions for which there is currently no effective treatment. Indications that AXIM® is pursuing through research and development include: MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), psychosis, PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS, and Crohn’s disease.
AXIM’s pipeline of intellectual property (IP) protected cannabinoid-based products include:
- MedChew RX™ – THC/CBD cannabinoid-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients
- RENECANN™ – the world’s first cannabigerol (CBG)-based skincare product line
- ORAXIMAX™ – the world’s first CBG-based oral care product line
- Suppocann™ – a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohn’s disease
- Ophthocann™ and Cannbleph™ – cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis
Recent news about AXIM’s mission is spreading from the U.S. to Canada, New Zealand and beyond, including Yahoo Finance, The Stock Radio.com, The Street, Westbrook Radio, Small Cap Voice, Inquisitr.com, Basis Home Infusion.com, The Blessed Source.com, Releaf, Penny Detective, Winning Pennies, Morning Star, EconoTimes.
AXIM® Biotech is a significant investment company for Medical Marijuana, Inc., which holds 14,943,650 shares of common stock and 500,000 shares of preferred stock representing 45.5% equity interest in the cutting-edge biotechnology innovator.
About Medical Marijuana Inc.
The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier cannabis and hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information on Medical Marijuana, Inc., please visit the company’s website at: www.medicalmarijuanainc.com
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Their companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.